rabbit polyclonal anti trka  (ABclonal Biotechnology)

Journal: Cell Reports Medicine

Article Title: A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration

doi: 10.1016/j.xcrm.2026.102937

Figure Lengend Snippet:

Article Snippet: Rabbit Polyclonal anti-TrkA , ABclonal , Cat# A4147; RRID: AB_2863195.

Techniques: Recombinant, Lysis, Hydroxyproline Assay, Enzyme-linked Immunosorbent Assay, Isolation, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Staining, Software

Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: HG-induced TrkA phosphorylation is associated with podocyte inflammation and injury. (A–D) Representative western blots show the levels of (A) TrkA and phospho-TrkA (Tyr490); (B) ERK, phospho-ERK and EGR1; (C) p35 and CDK5; and (D) IL-1β and TNF-α in MPC5 cells from the LG, HG, and LG + Man groups at 24 h (E) Representative immunofluorescence double staining shows the expression of phospho-TrkA (Tyr490) and synaptopodin in MPC5 cells from the LG, HG, and LG + Man groups. ****p < 0.0001. p < 0.05 was considered statistically significant; ns indicates not significant.

Article Snippet: Anti-phospho-TrkA (pTyr490) antibody (Cat. No. RA18018-100) was purchased from Origene (Rockville, MD, USA).

Techniques: Phospho-proteomics, Western Blot, Immunofluorescence, Double Staining, Expressing

Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: TrkA inhibition reduces the levels of p-TrkA, p-ERK, EGR1, p35, and CDK5 in the kidneys of db/db mice. (A–C) Representative western blots show the protein expression levels of (A) TrkA and phospho-TrkA (Tyr490), (B) ERK, p-ERK and EGR1, and (C) p35 and CDK5 in the kidney samples from the control, db/db, Inh-NC, and Inh-TrkA groups of mice. (D) Representative IF images show the expression of Synaptopodin (red) in the glomeruli of control, db/db, Inh-NC, and Inh-TrkA groups of mice (400X). ***p < 0.001. p < 0.05 was considered statistically significant; ns indicates not significant.

Article Snippet: Anti-phospho-TrkA (pTyr490) antibody (Cat. No. RA18018-100) was purchased from Origene (Rockville, MD, USA).

Techniques: Inhibition, Western Blot, Expressing, Control

Journal: Translational Oncology

Article Title: Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR

doi: 10.1016/j.tranon.2025.102577

Figure Lengend Snippet: The mutant NOTCH2-NTRK1 protein, ΔY490, reverses NSCLC cells resistance to osimertinib. (A) The 3D binding model of EGFR with the NOTCH2-NTRK1 fusion protein. EGFR was colored in marine, residues surrounding the binding pockets were shown as green sticks, and those of NTRK1 were shown as red sticks. The hydrogen bonds were depicted as green dashed lines. (B) Amino acid sequence of the NOTCH2-NTRK1 fusion protein. The predicted seven amino acid residues interacting with EGFR protein were colored in red. Tyrosine at position 490 in the intact NTRK1 protein (corresponding to position 329 in the NOTCH2-NTRK1 fusion protein) is marked in green. The truncated region (from Asn304 to Glu409) is underlined. (C) The co-localization between ΔY490 or Y490A variant with EGFR assessed by immunofluorescence staining. The HA (green) antibody was used to detect ΔY490 or Y490A variant. The EGFR (red) antibody was used to detect EGFR protein. DAPI (blue) was used to stain nuclei. Images were shown at 200 × magnification. (D) Co-IP between ΔY490 and Y490A variant with EGFR in BEAS-2B and H1975 cell lines. (IP: immunoprecipitation, IB: immunoblotting) (E) Dose-response curves of osimertinib for H1975-NOTCH2-NTRK1 variant cell lines. (F) Adhesion-dependent colony formation assay following 100 nM osimertinib treatment. ** P < 0.01, compared with the NOTCH2-NTRK1 group; ns , not significant, P ≥ 0.05; Data were presented as means ± SD from three biological replicates. (G) WB analysis of p-AKT, p-ERK1/2, p-EGFR (T669), and p-TRKA (Y490) protein levels assessed in H1975-NOTCH2-NTRK1 variant groups at 0, 0.5, 1, and 4 h after 100 nM osimertinib treatment. Grayscale values of the protein bands were measured using ImageJ software. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. Data were presented as means ± SD from two biological replicates.

Article Snippet: Antibodies for total AKT (#4691), phosphorylated AKT (Ser473) (#4060), total ERK (#4695), phosphorylated ERK (Thr202/Tyr204) (#4370), HA (C29F4) (#3724), EGFR (D38B1) (#4267), phosphorylated EGFR (Thr669) (D2F1) (#8808), Met (D1C2) (#8198) and phosphorylated TRKA (Tyr490) (#4619) were purchased from Cell Signaling Technology.

Techniques: Mutagenesis, Binding Assay, Sequencing, Variant Assay, Immunofluorescence, Staining, Co-Immunoprecipitation Assay, Immunoprecipitation, Western Blot, Colony Assay, Software

Journal: International Journal of Molecular Sciences

Article Title: Evaluation of NTRK Fusions Detection Method in Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma

doi: 10.3390/ijms27010336

Figure Lengend Snippet: IHC for TRK, TRKA, TRKB, and TRKC in esophageal squamous cell carcinoma (ESCC). ( A ) Representative images showing immunohistochemical (IHC) staining with anti-pan-TRK antibody in ESCC. Negative TRK staining (left panel), weak positive (middle panel), and moderate positive (right panel) are shown. Scale bars = 250 μm. ( B ) Representative images showing IHC staining using anti-TRKA, anti-TRKB, and anti-TRKC antibodies in ESCC. Positive TRKA, TRKB, and TRKC staining (upper panels) and negative staining (lower panels) are shown. Scale bars = 250 μm.

Article Snippet: After rinsing in PBS, the sections were incubated with ananti-pan-TRK antibody (# EPR17341 ; 1:50 dilution; Abcam, Cambridge, UK), anti-TRKA antibody (#2510; 12G8; 1:400 dilution; Cell Signaling Technology, Danvers, MA, USA), anti-TRKB antibody (#4607; 80G2; 1:2000 dilution; Cell signaling Technology), or anti-TRKC antibody (#3376; C44H5; 1:1000 dilution; Cell Signaling Technology) at 4 °C overnight.

Techniques: Immunohistochemical staining, Immunohistochemistry, Staining, Negative Staining